Literature DB >> 3288717

Parkinson's disease: an open label trial of pergolide in patients failing bromocriptine therapy.

S A Factor1, J R Sanchez-Ramos, W J Weiner.   

Abstract

Sixty-three patients with Parkinson's disease who failed bromocriptine therapy for various reasons were treated in an open-label trial of pergolide. The data were evaluated in a retrospective manner. Forty-six percent had a good response and tolerated the pergolide. A comparison of the outcomes regarding response and toxicity revealed that bromocriptine and pergolide act differently in individual patients. A trial of pergolide in Parkinsonian patients failing bromocriptine therapy may be therapeutically useful.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3288717      PMCID： PMC1032966          DOI： 10.1136/jnnp.51.4.529

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


  11 in total

1.  Long-term study of pergolide in Parkinson's disease.

Authors:  J Jankovic
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

2.  The pharmacological evaluation of pergolide mesylate as a potential anti-parkinson agent.

Authors:  W C Koller; W J Weiner; B I Diamond; P A Nausieda; H L Klawans
Journal:  Neuropharmacology       Date:  1980-09       Impact factor: 5.250

3.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

4.  Pergolide mesylate and idiopathic Parkinson disease.

Authors:  C M Tanner; C G Goetz; R H Glantz; S L Glatt; H L Klawans
Journal:  Neurology       Date:  1982-10       Impact factor: 9.910

5.  Dystonic foot response of Parkinsonism.

Authors:  P A Nausieda; W J Weiner; H L Klawans
Journal:  Arch Neurol       Date:  1980-03

6.  Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.

Authors:  C G Goetz; C M Tanner; R H Glantz; H L Klawans
Journal:  Neurology       Date:  1985-05       Impact factor: 9.910

7.  Comparison of pergolide and bromocriptine therapy in parkinsonism.

Authors:  P A LeWitt; C D Ward; T A Larsen; M I Raphaelson; R P Newman; N Foster; J M Dambrosia; D B Calne
Journal:  Neurology       Date:  1983-08       Impact factor: 9.910

8.  Double-blind trial of pergolide for Parkinson's disease.

Authors:  S G Diamond; C H Markham; L J Treciokas
Journal:  Neurology       Date:  1985-03       Impact factor: 9.910

9.  Pergolide in late-stage Parkinson disease.

Authors:  A E Lang; N Quinn; S Brincat; C D Marsden; J D Parkes
Journal:  Ann Neurol       Date:  1982-09       Impact factor: 10.422

10.  Painful Parkinson's disease.

Authors:  N P Quinn; W C Koller; A E Lang; C D Marsden
Journal:  Lancet       Date:  1986-06-14       Impact factor: 79.321
View more
  10 in total

1.  Parkinson's Disease: The Proper Use of Dopamine Receptor Agonists.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  1999-03       Impact factor: 3.598

2.  Effect of pergolide on endogenous and exogenous L-DOPA metabolism in the rat striatum: a microdialysis study.

Authors:  S Dethy; M A Laute; A Luxen; J Hildebrand; S Goldman
Journal:  J Neural Transm Gen Sect       Date:  1995

3.  Comparative Review of Dopamine Receptor Agonists in Parkinson's Disease.

Authors:  R J Uitti; J E Ahlskog
Journal:  CNS Drugs       Date:  1996-05       Impact factor: 5.749

4.  Clozapine-induced agranulocytosis and thrombopenia in a patient with dopaminergic psychosis.

Authors:  J Rudolf; M Grond; M Neveling; W D Heiss
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

Review 5.  Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.

Authors:  H D Langtry; S P Clissold
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

6.  Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.

Authors:  O Pogarell; T Gasser; J J van Hilten; S Spieker; S Pollentier; D Meier; W H Oertel
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-06       Impact factor: 10.154

7.  Effect of repeated administration of dopamine agonists on striatal neuropeptide mRNA expression in rats with a unilateral nigral 6-hydroxydopamine lesion.

Authors:  R Granata; G K Wenning; J Jolkkonen; P Jenner; C D Marsden
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 8.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

9.  Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.

Authors:  A Markham; P Benfield
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 6.497

Review 10.  Clinical pharmacology of dopamine agonists in Parkinson's disease.

Authors:  K W Lange
Journal:  Drugs Aging       Date:  1998-11       Impact factor: 4.271
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.